Malaysia's health ministry welcomes clinical trials on products containing cannabis extract for medical use: Deputy minister
KUALA LUMPUR: The Health Ministry in Malaysia welcomes applications to conduct clinical trials on products containing cannabis extract for medical purposes as there are no such trials being carried out at the moment, Deputy Health Minister Dr Noor Azmi said on Thursday (Jul 28)
Malaysia's Dangerous Drugs Act 1952, Poisons Act 1952 and the Sale of Drugs Act 1952 allow for cannabis extract to be supplied, imported, sold and used for medical purposes, research, or clinical trials, he said in response to a parliamentary question.
Dr Azmi said that companies that have adequate scientific proof of the effectiveness of products containing cannabis extract for medical purposes can submit an application to register the products to the Drug Control Authority of Malaysia.
Companies with medical cannabis products that have been approved abroad can also apply to have their products registered and marketed in Malaysia, he added.
"The MOH does not reject studies on the effectiveness of medical cannabis, it is time we follow the steps of 40 countries that have used it to treat diseases including cancer, depression, and epilepsy, we are ready to look at this," he said.
A proposal to separate the interpretations of cannabis, medical cannabis, and hemp from a legal aspect will depend on the findings of the special committee tasked to study and formulate the direction of the industry’s development, Dr Azmi said.
“Therefore the need to amend the Dangerous Drugs Act 1952 in connection with the control of cannabis and hemp including creating separate interpretations for cannabis and hemp depends on the Cabinet’s decision after reviewing the committee’s findings, taking into account the legal, socio-cultural, health, economy, Syariah law aspects and so on,” he added.